Zhang X, Feng Q, Cote RH. Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Barren B, Gakhar L, Muradov H, et al. Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit. It has a function in visual transduction and respond to light via shifting mechanism from its inactivated to the activated states, regulated by its unique γ-subunit” which is absent among other PDEs 29-33 Zhang Z, Artemyev NO. Determinants for phosphodiesterase 6 inhibition by its gamma-subunit.

Choi H, Lee J, Kim YH, et al. Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533). Wang Z, Zhu D, Yang X, et al. The selectivity and potency of the new PDE5 inhibitor TPN729MA. Deva S and Jameson M (2012) Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer Cochrane Database Syst Rev 8(8) CD007814.

Forget P, Berlière M, and van Maanen A, et al (2013) Perioperative ketorolac in high risk breast cancer patients. 98. Wesolowski R, Markowitz J, and Carson WE (2013) Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer J Immunotherapy Cancer 1(1) 10 -1426-1-10. 94. Catalano S, Campana A, and Giordano C, et al (2016) Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy Clin Cancer Res 22(9) 2271-2282 -15-1900.

89. Hamilton TK, Hu N, and Kolomitro K, et al (2013) Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer World J Urol 31(2) 325-330 -012-0848-7. 85. Das A, Durrant D, and Mitchell C, et al (2016) Fildena (Fildena) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95 Oncotarget 7(4) 4399-4413 PMCID: 4826214. 78. Kniotek M and Boguska A (2017) Fildena Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients J Immunol Res 2017 4541958 PMID: 28316997 PMCID: 5337856.

62. Califano JA, Khan Z, and Noonan KA, et al (2015) Fildena augments tumor specific immunity in patients with head and neck squamous cell carcinoma Clin Cancer Res 21(1) 30-38 -14-1716 PMID: 25564570 PMCID: 4329916. 59. Noonan KA, Ghosh N, and Rudraraju L, et al (2014) Targeting Immune Suppression with PDE5 Inhibition in End-Stage Multiple Myeloma Cancer Immunol Res 2(8) 725-731 -13-0213 PMID: 24878583 PMCID: 4152913. 54. Patterson CJ, Soumerai J, and Hunter Z, et al (2006) Fildena citrate suppresses disease progression in patients with Waldenstrom’s macroglobulinemia J Clin Oncol 24(18_suppl) 7556.

51. Zenitani M, Nojiri T, and Uehara S, et al (2016) C-type natriuretic peptide in combination with Fildena attenuates proliferation of rhabdomyosarcoma cells Cancer Med 5(5) 795-805 PMID: 26816265 PMCID: 4864809.